The current status of the diagnostic validity and treatment of generalized anxiety disorder

Current Opinion in Psychiatry

Volumn 15, Issue 2, 2002, Pages 157-162

  Hunt, Caroline Jane ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABECARNIL; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; LESOPITRON; OPIPRAMOL; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG DEPENDENCE; FUNCTIONAL DISEASE; HUMAN; INFANT MORTALITY; NEWBORN MORTALITY; PSYCHOTHERAPY; REVIEW; SEDATION; VALIDATION PROCESS;

EID: 0036183534     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200203000-00006     Document Type: Review

References (36)

1. The epidemiology of pure and comorbid generalized anxiety disorder: A review and evaluation of recent research
2. Generalized anxiety disorder: A risk factor for depression?
3. The epidemiology of generalized anxiety disorder
4. The diagnosis and nature of generalized anxiety disorder
5. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample
6. DSM-III-R generalized anxiety disorder in the national comorbidity survey
7. Generalized anxiety disorder (ICD10) in primary care from a cross-cultural perspective: A valid diagnostic entity?
8. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey
9. Factors predicting the clinical course of generalised anxiety disorder
10. Why do people with anxiety disorders become depressed? A prospective-longitudinal community study
11. Depressive comorbidity in children and adolescents with generalized anxiety disorder
12. Generalized anxiety disorder in older adults: Examining the relation between clinician severity ratings and patient self-report measures
13. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety
14. Major depression and generalised anxiety disorder. Same genes, (partly) different environments: Revisited
15. Evidence for genetic influences common and specific to symptoms of generalized anxiety and panic
16. Generalized anxiety disorder: Nature and course
17. Generalized anxiety disorder in children and adolescents
18. Psychotherapy for generalized anxiety disorder
19. The nonpharmacologic treatment of generalized anxiety disorder
20. (Generalized) anxiety disorder
21. Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder
22. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: Evaluation in a controlled clinical trial
23. Recommendations for a cost-offset model of psychotherapy allocation using generalized anxiety disorder as an example
24. Pharmacologic treatment of generalized anxiety disorder
25. Pharmacotherapy of generalized anxiety disorder
26. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial
27. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
28. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder
29. Treatment of anxiety disorders in the elderly: Issues and strategies
30. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder
31. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder
32. Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder
33. Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group
34. Long-term pharmacological treatment of generalized anxiety disorder
35. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial
36. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four week placebo-controlled dose-ranging study